Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass. (FINEST)
This study is ongoing, but not recruiting participants.
Sponsor:
Maquet Cardiovascular
Information provided by (Responsible Party):
Maquet Cardiovascular
ClinicalTrials.gov Identifier:
NCT01113892
First received: April 28, 2010
Last updated: April 25, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To demonstrate the patency and safety of vascular grafts: EXXCEL and FUSION Bioline. The investigators expect the performance of the grafts to be similar.
| Condition | Intervention |
|---|---|
|
Peripheral Arterial Occlusive Disease |
Device: vascular grafts |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Comparison of Safety and Primary Patency Between FUSION Vascular Graft With Bioline and EXXCEL Soft ePTFE (FINEST) |
Resource links provided by NLM:
Further study details as provided by Maquet Cardiovascular:
Primary Outcome Measures:
- Primary Efficacy [ Time Frame: 6 months ] [ Designated as safety issue: No ]Primary Patency
Secondary Outcome Measures:
- Secondary Efficacy [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Primary assisted patency
- Secondary patency
- Suture hole bleeding at the time of graft implantation procedure
- Safety [ Time Frame: Post-procedure, 30 days, 6 months, 12 months ] [ Designated as safety issue: Yes ]
Safety endpoint is the composite of Major Adverse Limb Events and Periprocedural Deaths, including:
- Major amputation
- Major graft reintervention
- Procedure-related death
| Enrollment: | 207 |
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | September 2013 |
| Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: EXXCEL Soft |
Device: vascular grafts
All devices will be used to treat patients with peripheral arterial occlusive disease
Other Name: vascular grafts
|
| Experimental: FUSION Bioline |
Device: vascular grafts
All devices will be used to treat patients with peripheral arterial occlusive disease
Other Name: vascular grafts
|
Detailed Description:
The study is a prospective, randomized, single-blind, two-arm, parallel group, multi-center study to evaluate the safety and efficacy of FUSION™ Vascular Graft with Bioline (heparin) coating, compared with EXXCEL Soft ePTFE in a peripheral bypass setting, to support a claim of substantial equivalence.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient requires either above-knee or below-knee femoral popliteal bypass;
- Patient has Category 1, 2, 3 4 or 5 chronic limb ischemia as defined by the Rutherford Categories - chronic limb ischemia severity classification scale.
- Patient is at least 21 years of age;
- Patient has postoperative life expectancy of >18 months;
- Patient is willing and able to provide written, informed consent.
Exclusion Criteria:
- Patient has a previous history of bypass in the diseased extremity (below iliacs);
- Patient had percutaneous transluminal angioplasty or stenting of the target femoral or popliteal artery at the anticipated site of the proximal or distal anastomosis within the previous 30 days;
- Patient has active infection in the region of graft placement;
- Patient has an acute arterial occlusion requiring an emergent intervention;
- Patient requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts;
- Patient has known hypersensitivity or contraindication to aspirin;
- Patient has known coagulation disorders including hypercoagulability;
- Patient has previous instance of Heparin induced Thrombocytopenia type 2 or has known hypersensitivity to heparin;
- Patient has severe chronic renal insufficiency, is undergoing hemodialysis. or has prior renal transplant;
- Patient had a stroke or MI within 6 weeks of the procedure;
- Patient is a woman of reproductive potential.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01113892
Show 28 Study Locations
Show 28 Study LocationsSponsors and Collaborators
Maquet Cardiovascular
Investigators
| Principal Investigator: | Alan Lumsden, MD | The Methodist Hospital System |
| Principal Investigator: | Nicholas J. Morrissey, MD | NY Presbyterian-Columbia U Medical Center |
More Information
No publications provided
| Responsible Party: | Maquet Cardiovascular |
| ClinicalTrials.gov Identifier: | NCT01113892 History of Changes |
| Other Study ID Numbers: | MCV00001506 |
| Study First Received: | April 28, 2010 |
| Last Updated: | April 25, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Arterial Occlusive Diseases Peripheral Arterial Disease Vascular Diseases Cardiovascular Diseases |
Atherosclerosis Arteriosclerosis Peripheral Vascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013